Comparison
Argireline vs. CJC-1295
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Cosmetic
Growth
CAS no.
616204-22-9
no data
Molecular weight
888.99 g/mol
3647.3 g/mol
Half-life
no data
144 h
Sequence
Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2YADAIFTNSYRKVLGQLSARKLLQDIMSR-DACMechanism of action
Argireline
Argireline is a synthetic hexapeptide whose sequence corresponds to the N-terminus of the SNAP-25 protein. In vitro it has been shown to competitively inhibit SNARE complex formation (necessary for vesicle fusion in neurotransmitter release). Topical application is intended — given very limited skin permeation — to attenuate cholinergic signalling at the neuromuscular endplate. The effect is orders of magnitude weaker than intramuscular botulinum toxin; the clinical translatability of the in-vitro observations to the skin microenvironment is contested.
CJC-1295
Synthetic analogue of growth-hormone-releasing hormone (GHRH), modified for extended half-life via a Drug Affinity Complex (DAC) binding to albumin. Acts on the pituitary GHRH receptor and stimulates endogenous growth-hormone release.
Evidence base
Highest evidence
Human trial
Human trial
Studies
3
3
of which in humans
2
2
Effects recorded
3
3
Open conflicts
1
1
Documented adverse events
1
3